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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) 
or bone marrow transplantation is used as a thera-
peutic modality for malignant and non-malignant 
hematological diseases, severe immunodeficiences 
and bone marrow aplasia (1). HSCT requires the applica-
tion of a conditioning regimen leading to myeloablation in 
order to create a space in the bone marrow of the recipient 
(2). Immunosuppression and destruction of neoplastic 
cells are other effects of high doses of chemotherapeutic 
drugs in combination or not with whole body radiotherapy. 
Oral mucositis (OM) is a common complication 
of cytotoxic chemotherapy and radiotherapy (3). This 
condition affects the mucosa of the gastrointestinal 
tract and especially the mucosa of the oral cavity and 
the oropharynx. It mainly affects patients subjected to 
aggressive myeloablative chemotherapy associated or 
not with radiotherapy, procedures that are also used in 
conditioning regimens for HCST (4,5). The incidence 
of mucositis in these patients is approximately 80 to 
100% (6). Clinically, mucositis starts in an asymptomatic 
manner, followed by the presence of erythema, burning 
complaints and increased sensitivity to hot and spicy 
foods. The erythema may progress to areas of desqua-
mation, followed by the appearance of ulcers associated 
with dysphagia and reduced oral ingestion, with a series 
of clinical consequences that affect the quality of life 
of the patients (6).
In view of the complexity of this toxicity, there 
is no standard of prevention or treatment, with a di-
versified management of OM. In our Bone Marrow 
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Transplant Unit (BMTU) of the University Hospital of 
the School of Medicine of Ribeirão Preto, University 
of São Paulo (UHSMRP/USP), Brazil, a mouthwash 
known as “Mucositis Formula” has been used for the 
treatment of clinical manifestations of OM, such as pain, 
erythema and ulceration. This oral rinse was developed 
at the UHSMRP/USP, Brazil, and is a combination of 
antiinflammatory (benzidamine), antifungal (nistatin) 
and anesthetic agents (neututocain) and distilled water. 
Rubenstein et al. (7) described experimental 
therapies using for the prevention or treatment of OM 
such as cryotherapy, benzidamine and palifermin, which 
reduced the severity of mucositis. According to Campos 
et al. (8), laser therapy offers as a new approach for the 
prevention and treatment of OM, reducing the pain and 
stimulating the salivary glands. 
In view of the small number of studies on the 
use of therapeutic laser for the prevention and treat-
ment of OM, this study compared the frequency and 
course of OM between groups of patients managed with 
therapeutic laser and conventional treatment (“Mucositis 
Formula”).
MATERIAL AND METHODS
The study was conducted at the BMTU of the 
UHSMRP/USP, Ribeirão Preto, SP, Brazil, from March 
2004 to September 2006, with the participation of 22 
patients subjected to allogeneic HSCT. The study was 
approved by the local Research Ethics Committee 
(Protocol #1534/2004) and all subjects gave written 
informed consent to participate in the study.
The patients were randomized into 2 groups ac-
cording to the order of hospitalization. Demographic 
characteristics of both groups are shown in Table 1. 
The conditioning regimen (high dose chemo-
therapy) was given to the 2 groups before stem cell infu-
sion. In group I, 2 patients received cyclophosphamide 
(D-5 to D-2, 50 mg/kg), 6 patients received busulfan 
(D-7 to D-4, 1 mg/kg) with cyclophosphamide (D-3 
to D-2, 60 mg/kg), 3 patients received busulfan (D-6 
to D-3, 1 mg/kg) with fludarabine (D-6 to D-2, 30 mg/
m2) and 1 patient received total body irradiation (D-6 
to D-4, 990 cGy total) and cyclophosphamide (D-3 to 
D-2, 60 mg/kg).
In group II, 1 patient received busulfan (D-7 to 
D-4, 1 mg/kg) with cyclophosphamide (D-3 to D-2, 60 
mg/kg), 2 patients received busulfan (D-6 to D-3, 1 mg/
kg) with fludarabine (D-6 to D-2, 30 mg/m2), 4 patients 
received total body irradiation (D-6 to D-4, 990 cGy 
total) and cyclophosphamide (D-3 to D-2, 60 mg/kg/) 
and 1 patient received fludarabine (30 mg/m2)/citarabine 
(2000 mg/m2)/mitoxantrone (10 mg/m2) from D-10 to 
D-7 and melfalan (D-3 to D-2, 70 mg/m2). 
All patients were subjected to treatment with 
methotrexate in combination with cyclosporine after 
transplantation for prevention of graft-versus-host 
disease. 
Inclusion criteria were: 12 years of age or older, 
both genders, hematologic or onco-hematologic disease, 
myeloablative conditioning regimen, and allogeneic 
hematopoietic stem cell transplantation. Exclusion cri-
teria were: autoimmune disease, non-myeloablative 
conditioning regimen, and haploidentical or autologous 
hematopoietic stem cell transplantation. Groups I and II 
were subjected to different protocols for the prevention 
and treatment of OM. 
The prevention phase for both groups started on 
the first day of conditioning and lasted until the initial 
clinical manifestation of mucositis in the oral cavity. 
The standard protocol for oral hygiene consisted of 
using soft-bristle toothbrushes and rinsing with 0.9% 
saline 4 times a day after meals, followed by rinsing 
with a benzidamine solution at the same frequency. 
In the beginning of 2006, the benzidamine solution 
was replaced by an alcohol-free 0.12% chlorhexidine 
Table 1. Demographic and clinical characteristics of the patients.
Group I
Laser therapy
(n=12)
Group II
Mucositis Formula
(n=10)
Mean age (years) 32.7 27.5
Gender
Male
Female
10
2
7
3
Diagnosis
Acute myeloid leukemia 5 3
Acute lymphoid leukemia 1 2
Chronic myeloid leukemia 3 2
Severe aplastic anemia 2 2
Myelodysplastic syndrome 1 1
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gluconate solution. 
The treatment phase for both groups started with 
the initial clinical manifestations of mucositis (e.g.: 
pain, edema, erythema) with follow-up until D+15 after 
transplantation, and consisting of the combination of 
the standard oral hygiene protocol with the use of the 
“Mucositis Formula” mouthwash. The composition of 
this rinse is: 0.15 g benzidamine, 1.13 g nistatin, 2 g 
neututocain and 10 mL distilled water. Benzidamine is 
an antiinflammatory agent that can reduce the production 
of pro-inflammatory cytokines and free radicals. Nistatin 
is a topical antifungal agent used for the treatment of 
oral candidiasis, the main opportunistic infection related 
to OM, and neututocain (an anesthetic) is used for pain 
relief. The difference between these 2 protocols was the 
inclusion of laser therapy both during the prevention and 
the treatment phase in group I.
Two scales were used for evaluation of OM: 
World Health Organization (WHO) Oral Toxicity Scale 
and Oral Mucositis Assessment Scale (OMAS). In the 
WHO scale, WHO 0 is defined no abnormality, WHO 1 
is erythema requiring no treatment, WHO 2 is presence 
of pain requiring no analgesics, difficulty in feeding, 
WHO 3 is ulceration, pain requiring analgesics, feeding 
is impossible and WHO 4 is necrosis, total parenteral 
nutrition.
The OMAS scale measures ulceration and ery-
thema. The assessment for ulceration in each site was 
scored from 0-3, with 0 representing no clinical lesion, 
1 representing an ulcer <1 cm2, 2 representing an ulcer 
of 1-3 cm2, and 3 representing an ulcer >3 cm2. The 
erythema was scored between 0-2, with 0 represent-
ing no erythema, 1 representing mild to moderate and 
2 representing severe erythema. The sites of the oral 
mucosa evaluated with the OMAS scale were: upper 
and lower lips (vermilion and mucosa), bilateral jugal 
mucosa, floor of the mouth, lateral tongue surface on 
both sides, and ventral surface of the tongue, to which 
therapeutic laser was applied in group I. According to 
the OMAS criteria, the OMAS score = 2.5 x [(∑ui/3nu) 
+ (∑ei/2ne)] was applied, with values between 0 and 5. 
∑ui is the total sum of ulceration, nu corresponds to the 
number of areas with ulceration, ∑ei is the total sum of 
erythema, and ne corresponds to the number of areas 
with erythema, according to Sonis et al. (19).
After discharge from the wards, a specific ques-
tionnaire about laser therapy was applied to group I to 
check if they had any lesion, oral pain, swallow pain and 
improvement after laser, without persuade results. The 
study was not blinded because group II was subjected 
only to the conventional treatment and not to sham laser. 
A low-intensity laser device (Twin Laser; MM 
Optics Ltda., São Carlos, SP, Brazil) purchased by our 
BMTU in 2003 was used in this study. The present 
study differed from the studies reported in the literature 
in that we compared the effect of laser therapy to that 
of conventional therapy. Several irradiation parameters 
were studied in order to determine the most adequate 
parameter settings to be used in the study. Two types 
of laser with the following diodes were used: indium 
gallium aluminum phosphide (InGaAlP) with 660 nm 
wavelength and gallium aluminum arsenide (GaAlAs) 
with 780 nm wavelength. The first diode emits a visible 
red laser, has lower penetration into biological tissue 
and is indicated for tissue repair, while the second diode 
emits infrared laser, has greater penetration capacity 
and it is indicated for analgesia. The laser applications 
were performed daily in the morning, once a day, and 
the 2 lasers were applied on alternate days using the 
same irradiation parameters: 25 mW output power, 10-s 
irradiation time and 6.3 J/cm2 dose per site and with 
direct contact with the mucosa.
The patients performed oral hygiene before the 
applications. The patients and the operator (VYK) wore 
protection eyeglasses during the procedure, which was 
carried out by the bedside on the ward, with the patient 
being isolated. Before the irradiations, the active tips 
of the pens were disinfected with 70% alcohol and 
covered with PVC film to avoid cross-contamination 
and at the end the PVC cover was discarded and the tip 
was disinfected again. The applications were performed 
up to D+15, coinciding or not with engraftment of 
hematopoietic stem cells. If engraftment was observed 
before this day, the irradiations were stopped in order 
not to impair the study. 
Data were analyzed by the non-parametric Wil-
coxon test for 2 independent samples, with the level 
of significance set at p<0.05. The exact version of the 
Wilcoxon test was used. Graphs were constructed using 
the Microsoft Office Excel 2003 and GraphPad Prisma 
4 and 5 softwares (GraphPad Software, Inc., San Diego, 
CA, USA).
RESULTS
The results obtained with the application of the 
Braz Dent J 20(3) 2009 
218 V.Y. Khouri et al.
WHO scale are presented in Figure 1. Comparison of 
the course of OM between patients of groups I and II, 
showed that group I presented a lower frequency of OM 
(Fig. 1) and the difference between groups was statisti-
cally significant (p=0.02). 
The mean grade of mucositis observed in group I 
was 1.75 ± 0.45, whereas group II presented a mean of 
2.45 ± 0.93. The difference between groups was statisti-
cally significant (p<0.01), according to the WHO scale. 
Regarding the size of ulcerations in the oral cavity as a 
whole, group I presenting fewer sites with ulcerations/
pseudomembranes and a smaller number of lesions 
compared to group II (Fig. 2). 
Using the OMAS scale, the mean frequencies 
of OM observed in groups I and II were 7.0 ± 3.2 and 
14.0 ± 8.3, respectively, with statistically significant 
difference (p=0.01) between the groups. Figure 3 illus-
trates the maximum OM values (ulceration + erythema) 
according to the OMAS score. It can be seen that the 
same values were obtained when laser therapy was used 
and the results were statistically significant (p=0.026). 
There was no clinical difference in the manifestation 
of erythema between groups, according to the OMAS 
scale. In group I, 10 patients presented mild/moderate 
erythema (83.3%) and mild/moderate to severe erythema 
occurred in 2 patients (16.6%), while in group II, 8 pa-
tients presented mild/moderate erythema (80%), severe 
erythema occurred in 1 patient (10%) and only 1 patient 
this group did not present erythema (10%). 
Regarding the answers to the questionnaire ap-
plied to group I, 50% of the patients reported fewer le-
sions, 10% more lesions, 40% did not show any lesions, 
75% reported not requiring analgesics for oral pain, 25% 
reported use the analgesics to oral pain, 100% pain to 
swallowing, 100% improvement after laser applications. 
DISCUSSION
OM is the most common and uncomfortable 
adverse effect in patients subjected to high doses of 
chemotherapy or radiotherapy and in patients subjected 
to HSCT. The clinical consequences are presence of pain 
and difficulty in feeding, swallowing and speaking (17).
Several therapies for the prevention and treatment 
of OM have been tested, The most recent one was the 
use of palifermin (human recombinant keratinocyte 
growth factor, KGF), which stimulates epithelial cells. 
The results were significant, with reduction of both the 
incidence and the duration of severe OM, and improve-
ment of pain (5).
Some therapeutic agents have shown insufficient 
evidence in the literature regarding the prevention and/
or treatment of mucositis, such as chlorhexidine (preven-
tion), aminofostine (treatment), and chamomile (preven-
tion and treatment), as reported by Rubenstein et al. (7).
Several studies have shown the benefits of thera-
peutic laser to prevent and treat oral mucositis and has 
several biological effects such as pain relief, antiinflam-
matory effects and acceleration of the regeneration of 
damaged tissues (10). Thus, laser therapy is a noninva-
sive technique that promotes pain relief and reduce the 
severity of oral mucositis in patients subjected HSCT, 
as reported by Jaguar et al. (20).
The first studies in patients involved the use of 
helium-neon (He-Ne) laser with a wavelength of 632.8 
Figure 1. Frequency of oral mucositis in groups I and II (p=0.02). Figure 2. Size of the lesions in groups I and II.
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nm (9), while current studies use several types of diodes 
such as the InGaAIP laser of 660 nm (18), the InGaAlP 
laser of 685 nm (14) and 660 nm (12), the GaAlAs laser 
of 830 nm (16). 
Eduardo et al. (18) reported the use of a InGaAIP 
laser (660 nm) with 40 mW and energy density of 4 J/
cm2 (for prevention of ulceration) or 6 J/cm2 (for treat-
ment of confirmed ulcerations) in 30 patients undergoing 
autologous (63.3%) or allogeneic (36.7%) HSCT. The 
results showed improvement of OM after laser therapy. 
According to Lopes et al. (14), laser treatment at several 
sites in the oral cavity during chemotherapy and radio-
therapy reduces the severity and duration of OM, oral 
pain and xerostomia. Antunes et al. (12) investigated the 
use InGAlP laser (660 nm) with 50 mW and 4 J/cm2 for 
prevention and reduction of OM in patients subjected to 
autologous or allogeneic HSCT. The WHO and OMAS 
scales were used simultaneously for the evaluation of 
mucositis in the oral cavity. The result was a reduction 
of the progression of the OM with better pain control 
with laser therapy. 
The use of laser therapy can be a powerful in-
strument to reduce of mucostis in patients undergoing 
chemotherapy. In a pilot clinical study (13), the pediatric 
patients were randomized to group I (prophylactic laser 
irradiation), group II (placebo laser irradiation) and 
group III (therapeutic laser irradiation). The AsGaAl 
laser (685 nm) was used, 35 mW, 2 J/cm2 per point of 
application, and OM was graded according to National 
Institute’s Common Toxicity Criteria. The use of laser 
for prophylaxis showed reduction of mucositis in group 
1 [8 patients (73%) presented OM grade 0] when com-
pared  to group 2 [2 patients (27%) had no OM]. The 
use of laser for treatment in group III was done when 
OM was diagnosed and these patients noted pain relief 
and without oral mucositis worsening after laser.
In the present study, the group I was irradiated 
with AlGaInP (660 nm) and GaAlAs (780 nm) lasers 
with 25 mW power, 6.3 J/cm2 dose, in 10 s time. The 2 
lasers were used alternately from the start of the con-
ditioning regimen until the D+15 post-transplantation. 
The WHO and OMAS scales were used for evaluating 
OM, according to Antunes et al. (12).
Comparison of the course of OM between the use 
to therapeutic laser (group I) and “Mucositis Formula” 
(group II) showed that group I presented a lower fre-
quency and severity of OM, according to WHO scale. 
With the application of the OMAS scale, 33.30% patients 
did not show any lesions and 66.60% showed lesions of 
<1 cm2, whereas group II developed a major frequency 
of OM and more extensive lesions. 
The use of therapeutic laser in the present study 
showed positive outcomes and the efficacy of laser to 
prevent and treat OM in patients subjected to HSCT, 
chemotherapy and radiotherapy, in accordance with data 
found in the literature (8,11-16,18,20) and the results 
were similar to those obtained by Antunes et al. (12). 
The outcomes of the present study add to the evidence 
that therapeutic laser can be an effective option for the 
prevention and treatment of OM in patients subjected to 
HSCT with the absence of adverse effects or discomfort, 
as suggested by other authors (11,13). 
However, few patients have been treated and 
most studies are not randomized. Thus, further studies 
with therapeutic laser on patients susceptible to OM are 
needed, preferably using a larger population. Neverthe-
less, in order to avoid conflicting results, it is necessary 
to standardize irradiation protocols for patients subjected 
to high doses of chemotherapy, followed or not by BMT. 
The availability of specialized professionals qualified 
for the use of laser according to safety guidelines is of 
paramount importance.
In conclusion, in the present study, patients 
treated with low-level laser therapy (group I) presented 
a lower frequency and progression of OM than those Figure 3. Evaluation of the severity of oral mucositis according 
to the OMAS score (p=0.026).
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that received conventional therapy with the “Mucositis 
Formula” (group II). The inclusion of laser therapy also 
reduced the number and severity of the lesions in patients 
of group I with established OM compared to group II. 
The present results add important evidence regarding 
the use of laser therapy as a standard method for the 
prevention and treatment of OM after allogeneic HSCT.
RESUMO
A mucosite oral (MO) afeta pacientes que são submetidos ao 
transplante de células-tronco hematopoéticas (TCTH) devido as 
altas doses de quimioterapia e/ou radioterapia. A proposta desta 
investigação foi realizar um estudo comparativo da freqüência 
e a evolução da MO entre os pacientes submetidos ao laser 
terapêutico e da terapia convencional (uso de solução de bo-
checho chamada “Fórmula para Mucosite”).Os pacientes foram 
submetidos ao regime de condicionamento mieloablativo antes 
da realização do TCTH alogênico.Vinte e dois pacientes foram 
selecionados e divididos em 2 grupos: grupo I foi irradiado com 
laser AlGaInP (660 nm) e laser GaAlAs (780 nm), potência de 
25 mW, dose de 6,3J/cm2, tempo 10 s, seguido do tratamento 
convencional; grupo II submetido apenas ao tratamento conven-
cional. Ambas as escalas da World Health Organization (WHO) 
e Oral Mucositis Assessment Scales (OMAS) foram utilizadas 
para avaliar os resultados. Os dados foram analizados pelo teste 
não-paramétrico de Wilcoxon, com p<0,05 considerado estatis-
ticamente significante. O grupo I apresentou menor frequência 
de MO (p=0,02) e menor média de acordo com as escalas WHO 
e OMAS (p<0,01 e p=0,01, respectivamente). Em conclusão, o 
laser reduziu a frequência e gravidade da MO, sugerindo que 
o laser terapêutico pode ser usado para ambos como uma nova 
forma de prevenção e tratamento da MO. 
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